Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral, Intravenous), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023)

March 2019 | 200 pages | ID: G989673EAB4EN
Azoth Analytics

Abstracts

EXECUTIVE SUMMARY

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Chemotherapy Drugs Market. The report analyzes the Chemotherapy Drugs Market, By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others), By Route of Administration (Oral, Intravenous, Others). The chemotherapy drugs market has been analyzed By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (U.S, Canada, United Kingdom, Germany, China and India) for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to Azoth Analytics research report “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral, Intravenous), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific and Rest of the World), By Country (U.S, Canada, United Kingdom, Germany, China and India)”, global market is projected to display a robust growth represented by a CAGR of 11.91% during 2018 – 2023.

On the basis of type of chemotherapy drug, plant alkaloids and antitumor antibiotics have been witnessing growth at a noteworthy rate over the past few years backed by effective use of these medications for the treatment of several varieties of cancers such as breast, ovarian, lung, bladder, prostate, melanoma, esophageal, as well as other types of solid tumors, etc. Amongst the regions, North America accounts for the largest regional share in the global chemotherapy drugs market in 2018. However, in the forecast period, the Asia Pacific region is anticipated to advance at the highest pace. Key factors driving the robust growth rate of Asia Pacific region include boosting production of pharmaceuticals, growing incidence of cancer along with government’s focus on medical infrastructural developments.

The report titled “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral, Intravenous), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific and Rest of the World), By Country (U.S, Canada, United Kingdom, Germany, China and India)” has covered and analyzed the potential of global chemotherapy drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global chemotherapy drugs market. Additionally, the report also highlights market entry strategies for various companies across the globe.

SCOPE OF THE REPORT

Global Chemotherapy Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023

• Global Chemotherapy Drugs Market – Size, Growth, Forecast
• By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others)
• By Route of Administration (Oral, Intravenous, Others)

Regional Markets – North America, Europe, APAC, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

• Regional Chemotherapy Drugs Market – Size, Growth, Forecast
• By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others)
• By Route of Administration (Oral, Intravenous, Others)

Country Analysis – U.S, Canada, United Kingdom, Germany, China and India (Actual Period: 2013-2017, Forecast Period: 2018-2023)

• Chemotherapy Drugs Market – Size, Growth, Forecast
• By Type of Drug (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics, Others)
• By Route of Administration (Oral, Intravenous, Others)

Other Report Highlights:

• Market Dynamics – Drivers and Restraints
• Market Trends
• SWOT Analysis
• Porter Five Force Analysis
• Policy and Regulatory Landscape
• Company Analysis – Pfizer, Eli Lilly & Company, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc, Novartis, Sanofi, Teva Pharmaceutical Industries Limited.

CUSTOMIZATION OF THE REPORT

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. STRATEGIC RECOMMENDATIONS

4. CHEMOTHERAPY DRUGS MARKET OUTLOOK

5. GLOBAL CHEMOTHERAPY DRUGS MARKET: GROWTH AND FORECAST

5.1 By Value (2013-2017)
5.2 By Value (2018-2023)

6. GLOBAL CHEMOTHERAPY DRUGS MARKET: SEGMENT ANALYSIS

6.1 Global Antimetabolite Chemotherapy Drugs Market, By Value (2013-2023)
6.2 Global Plant Alkaloid Chemotherapy Drugs Market, By Value (2013-2023)
6.3 Global Antitumor Antibiotic Chemotherapy Drugs Market, By Value (2013-2023)
6.4 Other Chemotherapy Drugs Market, By Value (2013-2023)
6.5 Global Chemotherapy Drugs Market Size, By Route of Administration: Breakdown (%)
  6.5.1 Global Chemotherapy Drugs Market Size, By Route of Administration, 2017 (%)
  6.5.2 Global Chemotherapy Drugs Market Size, By Route of Administration, 2023 (%)
6.6 Global Intravenous Chemotherapy Drugs Market, By Value (2013-2023)
6.6 Global Oral Chemotherapy Drugs Market, By Value (2013-2023)
6.7 Other Chemotherapy Drugs Market, By Value (2013-2023)

7. GLOBAL CHEMOTHERAPY DRUGS MARKET: REGIONAL ANALYSIS

7.1 Global Chemotherapy Drugs Market Size, By Region : Breakdown (%)
  7.1.1 Global Chemotherapy Drugs Market Size, By Region, 2017 (%)
  7.1.2 Global Chemotherapy Drugs Market Size, By Region, 2023 (%)
7.2 North America Chemotherapy Drugs Market: Growth and Forecast
  7.2.1 By Value (2013-2017)
  7.2.2 By Value (2018-2023)
  7.2.3 By Type of Drug, By Value (2013-2017)
  7.2.4 By Type of Drug, By Value (2018-2023)
  7.2.5 By Route of Administration, By Value (2013-2017)
  7.2.6 By Route of Administration, By Value (2018-2023)
7.3 North America Chemotherapy Drugs Market: Country Analysis (U.S and Canada)
  7.3.1 U.S Chemotherapy Drugs Market, By Value (2013-2023)
  7.3.2 Canada Chemotherapy Drugs Market, By Value (2013-2023)
7.4 Europe Chemotherapy Drugs Market: Growth and Forecast
  7.4.1 By Value (2013-2017)
  7.4.2 By Value (2018-2023)
  7.4.3 By Type of Drug, By Value (2013-2017)
  7.4.4 By Type of Drug, By Value (2018-2023)
  7.4.5 By Route of Administration, By Value (2013-2017)
  7.4.6 By Route of Administration, By Value (2018-2023)
7.5 Europe Chemotherapy Drugs Market: Country Analysis (Germany and U.K)
  7.5.1 Germany Chemotherapy Drugs Market, By Value (2013-2023)
  7.5.2 U.K Chemotherapy Drugs Market, By Value (2013-2023)
7.6 APAC Chemotherapy Drugs Market: Growth and Forecast
  7.6.1 By Value (2013-2017)
  7.6.2 By Value (2018-2023)
  7.6.3 By Type of Drug, By Value (2013-2017)
  7.6.4 By Type of Drug, By Value (2018-2023)
  7.6.5 By Route of Administration, By Value (2013-2017)
  7.6.6 By Route of Administration, By Value (2018-2023)
7.7 APAC Chemotherapy Drugs Market: Country Analysis (India and China)
  7.7.1 India Chemotherapy Drugs Market, By Value (2013-2023)
  7.7.2 China Chemotherapy Drugs Market, By Value (2013-2023)
7.8 ROW Chemotherapy Drugs Market: Growth and Forecast
  7.8.1 By Value (2013-2017)
  7.8.2 By Value (2018-2023)
  7.8.3 By Type of Drug, By Value (2013-2017)
  7.8.4 By Type of Drug, By Value (2018-2023)
  7.8.5 By Route of Administration, By Value (2013-2017)
  7.8.6 By Route of Administration, By Value (2018-2023)

8. GLOBAL CHEMOTHERAPY DRUGS MARKET DYNAMICS

8.1 Global Chemotherapy Drugs Market Drivers
8.2 Global Chemotherapy Drugs Market Restraints

9. GLOBAL CHEMOTHERAPY DRUGS MARKET TRENDS

10. PORTER FIVE FORCE ANALYSIS

11. SWOT ANALYSIS

12. POLICY AND REGULATORY LANDSCAPE

14. COMPANY PROFILES

14.1 Pfizer
14.2 Eli Lilly & Company
14.3 CELGENE Corporation
14.4 Bristol-Myers Squibb
14.5 Merck & Co., Inc.
14.6 GlaxoSmithKline plc
14.7 Novartis
14.8 Sanofi
14.9 Teva Pharmaceuticals Industries Limited

Figures & Tables

LIST OF FIGURES AND TABLES

Figure 1: Common Treatment Modalities for Cancer
Figure 2: Cancer Treatment Flowchart
Figure 3: Chemotherapy Drugs Market Segmentation Flowchart
Figure 4: Global Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 5: Global Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 6: Key factors driving of change in the global oncology market
Figure 7: Projected global population (In Billions)
Figure 8: Population ages 65 and above, By Select Region, 2013-2017 (% of total)
Figure 9: Projected global population aged 60 years & above (In Billions)
Figure 10: Global Health Expenditure Per Capita, By Select Countries, 2016 (In USD)
Figure 11: Global Health Expenditure Per Capita, (2012-2016, USD Trillion)
Figure 12: Global Burden of Cancer
Figure 13: Prevalence and Epidemiology of Cancer Worldwide
Figure 14: 5 Year Survival Rate, Breast and Colorectal Cancer
Figure 15: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted
Figure 16: Global Prevalence of Different Type of Cancer, 2017 (In Thousands)
Figure 17: Global Prevalence of Prostate Cancer (2013-2017, Thousands)
Figure 18: Oncologists per 1 Million of Population, By Select Country, 2018
Figure 19: Availability of New Cancer Drugs Launched in 2012-2016, By Select Country (As of 2017)
Figure 20: Global Antimetabolite Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 21: Global Antimetabolite Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 22: Global Plant Alkaloid Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 23: Global Plant Alkaloid Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 24: Global Alkylating Agent Drugs Market, By Value, 2013-2017 (USD Million)
Figure 25: Global Alkylating Agent Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 26: Global Anti-tumor Antibiotic Drugs Market, By Value, 2013-2017 (USD Million)
Figure 27: Global Anti-tumor Antibiotic Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 28: Other Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 29: Other Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 30: Global Chemotherapy Drugs Market Size, By Route of Administration, 2017 (%)
Figure 31: Global Chemotherapy Drugs Market Size,By Route of Administration, 2023 (%)
Figure 32: Global Intravenous Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 33: Global Intravenous Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 34: Global Oral Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 35: Global Oral Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 36: Other Chemotherapy Drugs Market, By Value, 2013-2017 (USD Million)
Figure 37: Other Chemotherapy Drugs Market, By Value, Forecast, 2018-2023 (USD Million)
Figure 38: Global Chemotherapy Drugs Market Size, By Region, 2017 (%)
Figure 39: Global Chemotherapy Drugs Market Size, By Region, 2023 (%)
Figure 40: North America Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 41: North America Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 42: North America GDP, 2012-2017 (USD Trillion)
Figure 43: North America GDP per capita, current prices, 2013-2023F (In USD)
Figure 44: Prevalence of Different Type of Cancer in North America in year 2016 & 2017 (In Hundreds)
Figure 45: North America, Cancer Incidence (In Millions)
Figure 46: North America, Cancer Incidence, By Route of Administration, 2019E (In %)
Figure 47: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
Figure 48: North America Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million)
Figure 49: North America Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million)
Figure 50: North America Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million)
Figure 51: North America Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million)
Figure 52: U.S. Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 53: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %)
Figure 54: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %)
Figure 55: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %)
Figure 56: Estimated New Cases of Cancer in the United States, 2014-2018 (In Thousands)
Figure 57: Estimated New Cases of Cancer in the United States, By State, 2018
Figure 58: Estimated Numbers of US Cancer Survivors (As of January 1, 2016)
Figure 59: Estimated Numbers of US Cancer Survivors (As of January 1, 2026F)
Figure 60: Factors Influencing Patient Out-of-Pocket Costs for Cancer Medicines
Figure 61: United States, Top Players in the chemotherapy drugs market, By Company Share, 2017 (%)
Figure 62: Canada Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 63: Cancer Burden in Canada, 2017
Figure 64: Prevalence of Different Type of Cancer in Canada, 2016 & 2017 (In Hundreds)
Figure 65: Cancer Fact Sheet of Canada, 2017
Figure 66: Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Figure 67: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 68: North America Chemotherapy Drugs Market, Country Share, 2013-2017 (% of Total)
Figure 69: North America Chemotherapy Drugs Market, Country Share, 2018F-2023F (% of Total)
Figure 70: Europe Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 71: Europe Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 72: Europe, Cancer Incidence, 2019E-2035F (In Millions)
Figure 73: Europe, Cancer Incidence, By Type, 2019E
Figure 74: Prevalence of Different Type of Cancer in Western Europe in year 2016 & 2017 (In Thousands)
Figure 75: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Figure 76: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
Figure 77: Breakdown of Total Health Expenditure in Europe, 2018 (%)
Figure 78: Major Players in Chemotherapy Drugs Market in Europe
Figure 79: Europe Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million)
Figure 80: Europe Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million)
Figure 81: Europe Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million)
Figure 82: Europe Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million)
Figure 83: Germany Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 84: Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Figure 85: Prevalence of Different Type of Cancer in Germany in year 2016 & 2017 (In Hundreds)
Figure 86: U.K Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 87: Cancer Statistics in the United Kingdom
Figure 88: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Figure 89: Europe Chemotherapy Drugs Market, Country Share, Historic, 2013-2017(% of Total)
Figure 90: Europe Chemotherapy Drugs Market, Country Share, Forecast, 2018-2023 (% of Total)
Figure 91: APAC Chemotherapy Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 92: APAC Chemotherapy Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 93: Estimated number of deaths from prostate cancer in 2012 and 2030
Figure 94: World health expenditure as % of GDP
Figure 95: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
Figure 96: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Figure 97: APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 98: APAC Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million)
Figure 99: APAC Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million)
Figure 100: APAC Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million)
Figure 101: APAC Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million)
Figure 102: India Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 103: Key factors affecting the Indian Healthcare Industry
Figure 104: India, Total Population, 2013-2023F (In Billion)
Figure 105: India, Share of Urban Population, 2012-2017 (In %)
Figure 106: India, GDP Growth Per Year, 2015-2019 (In %)
Figure 107: India, Total deaths due to cancer, 2018
Figure 108: Top 5 forms of cancer in men and women in India
Figure 109: China Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 110: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 111: China, Share of Urban Population, 2012-2017 (In %)
Figure 112: China, Total Population, 2013-2021F (In Billion)
Figure 113: Prevalence of Different Type of Cancer in China in year 2016 & 2017 (In Hundreds)
Figure 114: Number of new cases, Males (all ages), 2018 (In %)
Figure 115: Number of new cases, Females (all ages), 2018 (In %)
Figure 116: China, Cancer Mortality Rate, By Cancer Site, 2018
Figure 117: APAC Chemotherapy Drugs Market, Country Share, Historic, 2013-2017 (% of Total)
Figure 118: APAC Chemotherapy Drugs Market, Country Share, Forecast, 2018-2023 (% of Total)
Figure 119: ROW Chemotherapy Drugs Market Size, By Value, 2013-2023 (USD Million)
Figure 120: Middle East and North Africa, GDP, 2012-2017 (In USD Trillion)
Figure 121: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %)
Figure 122: Prevalence of Different Type of Cancer in Middle East and North Africa in year 2016 & 2017 (In Hundreds)
Figure 123: Prevalence of Different Type of Cancer in Brazil in year 2016 & 2017 (In Hundreds)
Figure 124: ROW Chemotherapy Drugs Market: By Type of Drug, By Value, 2013-2017 (USD Million)
Figure 125: ROW Chemotherapy Drugs Market: By Type of Drug, By Value, 2018E-2023F (USD Million)
Figure 126: ROW Chemotherapy Drugs Market: By Route of Administration, By Value, 2013-2017 (USD Million)
Figure 127: ROW Chemotherapy Drugs Market: By Route of Administration, By Value, 2018E-2023F (USD Million)
Figure 128: Drug Discovery and Development, Approximate Timeline
Figure 129: Pfizer, Revenue, 2013-2017 (In USD Billion)
Figure 130: Pfizer, Revenue, By Business Segment, 2017 (In %)
Figure 131: Pfizer, Revenue, By National Market, 2015-2017 (In %)
Figure 132: Pfizer, Oncology Revenue, 2015-2017 (In USD Million)
Figure 133: Eli Lilly & Company, Revenue, 2013-2017 (In USD Billion)
Figure 134: Eli Lilly & Company, Revenue, By Business Segment, 2017 (In %)
Figure 135: Eli Lilly & Company, Net Sales, By Geographic Region, 2017 (In %)
Figure 136: CELGENE Corporation, Revenue, 2013-2017 (In USD Million)
Figure 137: CELGENE Corporation, Net Sales, By Geographic Region, 2017 (In %)
Figure 138: Bristol-Myers Squibb, Revenue, 2013-2017 (In USD Million)
Figure 139: Bristol-Myers Squibb, Revenue, By Business Segment, 2017 (In %)
Figure 140: Bristol-Myers Squibb, Net Sales, By Geographic Region, 2017 (In %)
Figure 141: Merck & Co., Inc., Revenue, 2013-2017 (In USD Million)
Figure 142: Merck & Co., Inc., Net Sales, By Geographic Region, 2017 (In %)
Figure 143: GlaxoSmithKline plc, Revenue, 2013-2017 (In USD Million)
Figure 144: GlaxoSmithKline plc, Revenue, By Business Segment, 2017 (In %)
Figure 145: GlaxoSmithKline plc, Net Sales, By Geographic Region, 2017 (In %)
Figure 146: Novartis, Revenue, 2014-2018 (In USD Million)
Figure 147: Novartis, Net Sales, By Business Segment, 2017 (In %)
Figure 148: Sanofi, Revenue, 2013-2017 (In USD Million)
Figure 149: Sanofi , Revenue, By Business Segment, 2017 (In %)
Figure 150: Sanofi, Net Sales, By Geographic Region, 2017 (In %)
Figure 151: Teva Pharmaceutical INDUSTRIES LIMITED, Revenue, 2013-2017 (In USD Million)
Figure 152: Teva Pharmaceutical INDUSTRIES LIMITED, Revenue, By Business Segment, 2017 (In %)
Figure 153: Teva Pharmaceutical INDUSTRIES LIMITED, Net Sales, By Geographic Region, 2017 (In %)
List of Tables
Table A: Approach and Limitations of Common Treatment Modalities for Cancer
Table B: Recent Company Acquisitions and Mergers in Chemotherapy Drugs Market
Table C: Germany, Healthcare Related Statistics, 2017
Table D: Estimated number of people living with cancer, 2020F and 2030F
Table E: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table F: India, Cancer Statistics